Kyowa Hakko Kirin Co., Limited

Kyowa Hakko Kogyo Co., Ltd.

Akihisa Mori

Hiroshi Kase

Naoki Seno

Shizuo Shiozaki

Akira Karasawa

Yutaka Ohsawa

Minoru Kobayashi

Yoshihisa Kuwana

Yutaka Waki

Dayao Zhao

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

Pharmaceutical composition containing KW-6002 and fluoxetine or paroxentine

Pharmaceutical composition

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine Areceptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HTantagonist or the like), and the like.

The present invention provides methods of treating restless legs syndrome or related disorders, comprising administering an effective amount of at least one adenosine Areceptor antagonist to a patient in need thereof. More preferably the adenosine Areceptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.

Adenosine A2A receptor antagonists for treating restless legs syndrome or nocturnal myoclonus

The present invention is directed to methods of treating movement disorders by administering an effective amount of one or more adenosine Areceptor antagonists to a patient in need thereof. The present invention also provides methods of decreasing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating Parkinson's disease patients with sub-clinically effective doses of L-DOPA by combining L-DOPA treatment with an effective amount of one or more adenosine Areceptor antagonists (i.e., L-DOPA sparing effect). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one adenosine Areceptor antagonist, L-DOPA and a dopamine agonist and/or a COMT inhibitor and/or a MAO inhibitor. The present invention further provides methods of prolonging effective treatment of Parkinson's disease by administering an adenosine Areceptor antagonist singly or together with a dopamine agonist, and/or a COMT inhibitor, and/or a MAO inhibitor without prior or subsequent administration of L-DOPA, delaying or removing on-set of L-DOPA motor complication.

Methods of treating patients suffering from movement disorders

[object Object]

Growing community of inventors

Narashino, Japan

Akihisa Mori